The Impact of Polypharmacy on Medication Problems and Clinical Outcomes in Patients with Stage 5 Chronic Kidney Disease Undergoing Hemodialysis: A Narrative Review
DOI:
https://doi.org/10.59141/jrssem.v5i12.1581Keywords:
Cost Burden, Drug-Related Problems, Hemodialysis, Quality of Life, PolypharmacyAbstract
Patients with stage 5 chronic kidney disease (CKD) who undergo routine hemodialysis (HD) often receive a complex treatment regimen (polypharmacy) to control comorbidities. This condition increases susceptibility to drug-related problems (DRPs) due to pharmacokinetic and pharmacodynamic changes after nephron damage. This narrative review aims to evaluate the impact of polypharmacy on the incidence of drug problems (DRPs) and its implications on various clinical outcomes, quality of life, and cost burden in stage 5 CKD patients with routine HD. This writing used a narrative review method through searching literature from various scientific data sources such as Google Scholar, PubMed, and Scince Direct, as well as national journals with a publication time span of the last 5-10 years. Literature analysis showed that polypharmacy was strongly correlated with a high incidence of moderate to major drug interaction potential (DDI) (49–89%) and drug side effect multiplication (ADRs). The use of drugs without proper dosage adjustment to the dialysis circuit triggers therapy failure. Monitoring of therapeutic outputs has been proven to integrate the dimensions of clinical data, laboratory biomarkers, economic aspects, and drug burden reduction through deregulation. Polypharmacy in ESRD-HD patients poses massive clinical and financial problems. The active involvement of clinical pharmacists through treatment reconciliation and selection of drug types with safe non-renal elimination is crucial to minimize the risk of toxicity, optimize clinical outcomes, and improve patients' quality of life.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2026 Primatia Adrini Hapsari, Yulistiani Yulistiani, Githa Fungie Galistiani
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-ShareAlike 4.0 International. that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.
